Insider · CIK 0001855643

Warmuth Markus

Reports to the SEC for 1 company · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001855643

Forms 4 and 5

Insider transactions

19 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-16	GLUEMonte Rosa Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−9,500 sh	$23.18	−$220K	585,038
2026-06-01	GLUEMonte Rosa Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−4,998 sh	$19.41	−$97K	595,006
2026-06-01	GLUEMonte Rosa Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−468 sh	$19.73	−$9,231.862	594,538
2026-05-01	GLUEMonte Rosa Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−5,467 sh	$18.92	−$103K	600,004
2026-04-14	GLUEMonte Rosa Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−8,000 sh	$17.64	−$141K	605,471
2026-03-02	GLUEMonte Rosa Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−5,466 sh	$17.92	−$98K	613,471
2026-01-07	GLUEMonte Rosa Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−3,707 sh	$23.24	−$86.2K	620,696
2026-01-07	GLUEMonte Rosa Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−1,450 sh	$23.88	−$34.6K	619,246
2026-01-07	GLUEMonte Rosa Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−309 sh	$24.57	−$7,593.242	618,937
2026-01-05	GLUEMonte Rosa Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−10.1K sh	$15.17	−$154K	624,403
2026-01-02	GLUEMonte Rosa Therapeutics, Inc.A Award	Director, President & CEO	AAward	+90K sh	—	—	634,538
2026-01-02	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+406K sh	—	—	406,000
2025-01-02	GLUEMonte Rosa Therapeutics, Inc.A Award	Director, President & CEO	AAward	+128K sh	—	—	544,538
2025-01-02	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+575K sh	—	—	575,000
2024-01-02	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+346K sh	—	—	346,000
2023-01-03	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+472K sh	—	—	472,000
2022-03-01	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+316K sh	—	—	315,600
2021-06-23	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+142K sh	—	—	141,623
2021-04-12	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+539K sh	—	—	538,517

Recent filings

Accepted (ET)
Jul 174
Warmuth Markus0001193125-26-307791
SEC(opens sec.gov)
Jun 24
Warmuth Markus0001193125-26-253472
SEC(opens sec.gov)
May 54
Warmuth Markus0001193125-26-206344
SEC(opens sec.gov)
Apr 154
Warmuth Markus0001193125-26-156981
SEC(opens sec.gov)
Mar 44
Warmuth Markus0001193125-26-091733
SEC(opens sec.gov)
Jan 94
Warmuth Markus0001193125-26-008902
SEC(opens sec.gov)
Jan 54
Warmuth Markus0001193125-26-002389
SEC(opens sec.gov)
Jan 64
Warmuth Markus0000950170-25-002100
SEC(opens sec.gov)
Jan 44
Warmuth Markus0001209191-24-000767
SEC(opens sec.gov)
Jan 44
Warmuth Markus0001209191-23-000956
SEC(opens sec.gov)
Mar 24
Warmuth Markus0000899243-22-008673
SEC(opens sec.gov)
Jun 254
Warmuth Markus0000899243-21-025976
SEC(opens sec.gov)

Companies

Monte Rosa Therapeutics, Inc.Director, President & CEOGLUE

Address

MONTE ROSA THERAPEUTICS, INC. 321 HARRISON AVENUE, SUITE 900

BOSTON, MA, 02118